News Virax Biolabs Group Limited

Equities

VRAX

KYG9495L1251

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-24 pm EDT			5-day change	1st Jan Change
0.6636 ^USD	+0.85%		+2.00%	-54.55%

Jan. 12	Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2023	CI
2023	Virax Biolabs Group Limited Forges Strategic Research Collaboration with University of Manchester and Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Virax Biolabs to Participate at ESCMID Global 2024	Apr. 17	AQ
Virax Biolabs : to Participate at ESCMID Global 2024 - Form 6-K	Apr. 16	PU
Virax Biolabs : Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency - Form 6-K	Mar. 15	PU
Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2023	Jan. 12	CI
Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients	Dec. 22	AQ
Virax Biolabs Group Limited Forges Strategic Research Collaboration with University of Manchester and Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients	Dec. 21	CI
Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation	Dec. 15	AQ
Top Premarket Gainers	Dec. 12	MT
Virax Biolabs : Notice of 2023 Annual General Meeting of Shareholders To Be Held on - Form 6-K	Nov. 08	PU
Virax Biolabs : CLAWBACK POLICY - Form 6-K	23-10-31	PU
Virax Biolabs Group Limited announced that it has received $2.15 million in funding	23-10-16	CI
Virax Biolabs Group Limited announced that it expects to receive $2.15 million in funding	23-10-11	CI
Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar	23-09-13	AQ
Virax Biolabs : Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar - Form 6-K	23-09-12	PU
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum	23-09-04	AQ
Virax Biolabs Group Names Nigel McCracken Operating Chief.	23-09-01	MT
Virax Biolabs Group Limited Announces Management Changes	23-09-01	CI
Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid	23-08-04	AQ
Virax Biolabs : Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid - Form 6-K	23-08-03	PU
Certain Ordinary Shares of Virax Biolabs Group Limited are subject to a Lock-Up Agreement Ending on 21-JUL-2023.	23-07-20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Virax Biolabs Group Limited

Equities

VRAX

KYG9495L1251

Summary

Filters